COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS THAT ARE AMELIORATED BY INHIBITION OF HDAC

The present invention relates to compounds of formula (I) and (IV), and pharmaceutically acceptable salts, tautomers, stereoisomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are for usein the treatment of disorders that are ameliorated by inh...

Full description

Saved in:
Bibliographic Details
Main Authors LAUFER, RALPH, HARPER, STEVEN, ALTAMURA, SERGIO, GAMBARI, ROBERTO, BRESCIANI, ALBERTO, MONTEAGUDO, EDITH, PACE, PAOLA, SUMMA, VINCENZO, FABBRINI, DANILO, NIZI, EMANUELA, BREVEGLIERI, GIULIA
Format Patent
LanguageEnglish
French
Published 13.02.2014
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to compounds of formula (I) and (IV), and pharmaceutically acceptable salts, tautomers, stereoisomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are for usein the treatment of disorders that are ameliorated by inhibition of HDACsuch ascancer and hemoglobinopathieslike beta-thalassemia or sickle cell anemia. La présente invention concerne des composés de Formule (I) et (IV), et des sels, tautomères, stéréoisomères pharmaceutiquement acceptables de ceux-ci, qui sont des inhibiteurs de l'histone désacétylase (HDAC). Les composés de la présente invention sont destinés à l'utilisation dans le traitement de troubles qui sont améliorés par l'inhibition de HDAC, tels que le cancer et des hémoglobinopathies telles que la beta-thalassémie ou la drépanocytose.
Bibliography:Application Number: WO2013EP66524